Interest in psychedelic therapies is surging due to their potential for treating conditions such as PTSD, treatment-resistant depression (TRD), OCD, and others. This paper explores three key factors related to psychedelics:
- Emerging Business Models – The types of organizations that are driving innovation in psychedelics
- The Costs Beyond the Drug – How psychedelic-assisted therapy (AT) will present new challenges to payments and the provision of care
- The Potential Value of Digital Health – How digital health could provide relief to the cost-pressures associated with psychedelic-AT, potentially facilitating better access and reimbursement while also improving care
